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Background: The new European pharmacovigilance legislation has been suggested as marking the beginning of a
new chapter in drug safety, making patients an important part of pharmacovigilance. In Sweden since 2008 it has
been possible for consumers to report adverse drug reactions (ADRs) to the Medical Products Agency (MPA), and
these reports are now understood as an increasingly valuable contribution in the monitoring of safety aspects in
medicines. Already in 2002 it was possible to report experiences with medicines to the non-profit and independent
organization Consumer Association for Medicines and Health (KILEN) through a web-based report form with an
opportunity to describe ADR experiences in free text comments. The aim of this study was to qualitatively analyze
the free text comments appended to consumer reports on antidepressant medication.
Methods: All reports of suspected adverse reactions regarding antidepressant medications submitted from January
2002 to April 2009 to KILEN’s Internet-based reporting system in Sweden were analyzed according to reported
narrative experience(s). Content analysis was used to interpret the content of 181 reports with free text comments.
Results: Three main categories emerged from the analyzed data material: (1) Experiences of drug treatment with
subcategories (a) Severe psychiatric adverse reactions, and (b) Discontinuation symptoms; (2) Lack of communication
and (3) Trust and distrust. A majority of the reports to KILEN were from patients experiencing symptoms of mental
disturbances (sometimes severe) affecting them in many different ways, especially during discontinuation. Several
report included narratives of patients not receiving information of potential ADRs from their doctor, but also that
there were no follow-ups of the treatment. Trust was highlighted as especially important and some patients
reported losing confidence in their doctor when they were not believed about the suspected ADRs they
experienced, making them attempt to discontinue their antidepressant treatment on their own.
Conclusions: The present study indicates that free text comments as often contained in case reports directly
submitted by patients can be of value in pharmacovigilance and provide important information on how a drug
may affect the person using it and influence his or her personal life.* Correspondence: andreas.vilhelmsson@nhv.se
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Figure 1 Flow diagram of selected consumer reports to KILEN.
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The new European pharmacovigilance legislation (Dir-
ective 2010/84/EU) (Regulation 1235/2010) [1] that
came into force in July 2012 has been suggested as
marking the beginning of a new chapter in drug safety
[2]. Its purpose is to further accentuate patient influ-
ence, and all EU countries are now obliged to intro-
duce patient/consumer reporting to their spontaneous
reporting systems, making patients an important part
of pharmacovigilance. Since under-reporting by health
professionals is a well-recognized problem by the
World Health Organization (WHO) [3], the Organization
proclaims consumer reporting to be of great import-
ance in safeguarding a pharmacovigilance program
that will help each patient to receive optimum ther-
apy, and on a population basis will lead to ensure
the acceptance and effectiveness of public health
programs [4].
Previous research has indicated that consumer
reporting of adverse drug reactions (ADRs) may add
value to healthcare professionals’ (HCP) reports by
identifying possible new reactions [5-10]. In Sweden
since 2008 it has been possible for consumers to sub-
mit reports to the Medical Products Agency (MPA),
and these reports are now understood as an increas-
ingly valuable contribution in the monitoring of safety
aspects in medicines [11]. The MPA also offers the
opportunity for the consumer to use free text in de-
scribing the reaction(s). However, these descriptions
have not previously been subjected to qualitative analysis
or been published. In order to strengthen consumer rights
within the health care sector, the non-profit and inde-
pendent organization Consumer Association for Medi-
cines and Health (KILEN) has provided the opportunity
for consumers to report their perceptions and experiences
of using medicines. KILEN had already established a con-
sumer database in 1997 to collect consumer reports,
mainly focusing on benzodiazepines and antidepressants.
KILEN was created in 1992, but their co-workers had
already a long history of working with pharmaceutical
drug dependency when in the 1960s it became clear that
the new benzodiazepines were causing dependency and
harm. Since 2002 it has also been possible to report sus-
pected ADRs to this organization through a web-based
report form with the opportunity to add free text com-
ments of the experience(s) (www.kilen.org). Previous
research on the KILEN material has shown that con-
sumer reports may contribute important information
regarding more serious psychiatric adverse reactions
following antidepressant treatment [9]. However, the
free text comments were not scrutinized or analyzed.
This study, therefore, aimed to qualitatively analyze
the free text comments to consumer reports on anti-
depressant medication.Methods
All reports of suspected adverse reactions regarding
antidepressant medications submitted from January 2002
to April 2009 to KILEN’s Internet-based reporting sys-
tem in Sweden were analyzed according to reported nar-
rative experience(s). According to WHO, a side effect is
an unintended effect of a pharmaceutical product (oc-
curring at doses normally used by a patient) and where
there is a relation to the pharmacological properties of
the drug whilst an adverse drug reaction (ADR) is
defined as a response to a medicine which is noxious
and unintended (occurring at doses normally used in
man) and where the response of the patient is of import-
ance, in which individual factors may play an important
[3]. Since the reports to KILEN contained individual
responses to a drug reported as severe and noxious we
decided to use the latter. The KILEN compilation and
coding system is described in a previous study [9]. As
Figure 1 shows, of 442 individual antidepressant reports,
393 individuals also provided a longer description of the
ADR experience as free text (89%). A total of 202 anti-
depressant reports concerned depression as diagnosis
(most reported cause for prescription) and included a
narrative of the experiences (46%). A total of 21 reports
were excluded since they were reported by someone
other than the patient (5) or contained too little infor-
mation (16). Included in the study, therefore, were 181
reports (41%) with narrative.
The project was approved by the Regional Ethics Re-
view Board in Gothenburg, Sweden (No. 319–10).
Data analysis
Content analysis was used to interpret the patients’
accounts. Content analysis here refers to a qualitative data
reduction and sense-making effort that takes a volume of
qualitative material and attempts to identify core consist-
encies and meanings [12]. The procedure is basically as
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egory; the coded data are then analyzed and presented
[13]. Creating categories is the core feature of qualitative
content analysis and refers to a descriptive level of con-
tent; a category often includes a number of sub-categories
[14]. All 181 included consumer narratives on depression
and antidepressant treatment were read thoroughly sev-
eral times in order to get an understanding of their mean-
ing. The content of these narratives was then sorted into
different main categories and read again, which resulted in
subcategories and sometimes new main categories [14].
As Graneheim and Lundman argue, qualitative content
analysis interpretation involves a balancing act, where on
one hand it is impossible and undesirable for the re-
searcher not to add a particular perspective to the phe-
nomena under study, but on the other hand the
researcher must ‘let the text talk’ and not impute meaning
that is not there [14]. Therefore, all authors were involved
in analyzing the themes that emerged from the data and
were also responsible for reading and confirming the ana-
lysis. The authors discussed the analyses – the coding,
categorization and interpretation of the results – through-
out the work process to gain a mutual understanding. This
process was also valid for the selection of quotations de-
scribing common experiences found within certain cat-
egories. This selection was also made in order to
problematize the role of the researcher and to avoid miss-
ing out on important information or exaggerate specific
content.Results and discussion
Of the 181 consumer reports included and analyzed,
women contributed 135 (75%) and men 38 (21%). The
antidepressants most reported for depression as diagno-
sis were Sertraline (23.8%), Citalopram (23.8%), Venla-
faxine (23.2%), Mirtazapine (10.5%), Paroxetine (7.7%),
Escitalopram (6.1%) and Fluoxetine (5.0%). As described
in Table 1, three main categories emerged from the ana-
lysis of the KILEN data: (1) Experiences of drug treat-
ment with subcategories (a) Severe psychiatric adverseTable 1 Categorization of the analyzed components – examp
reports1
Meaning unit Condensed mea
“Difficulties concentrating at work, having suicidal
thoughts.”
Patient experienc
“And when the death wish comes, I become so afraid that
I start again.”
Patient experienc
when trying to en
“When I first started taking it I received NO [sic!] warnings
of adverse drug reactions.”
Patient received n
from the doctor.
“Decided that after three years of ‘chemical terror’ to
discontinue, WITHOUT [sic!] doctor’s approval.”
Patients decided
without telling th
1 Categorization according to Graneheim & Lundman (2004).reactions, and (b) Discontinuation symptoms, (2) Lack of
communication and (3) Trust and distrust.Experiences of drug treatment
A main category within the KILEN material concerned
patients’ experiences of suspected adverse reactions dur-
ing their treatment with antidepressants. Particularly ser-
ious psychiatric adverse symptoms were perceived as
something difficult during and after treatment, and espe-
cially during discontinuation.Severe psychiatric adverse reactions
A majority of the reports to KILEN were from patients
experiencing symptoms of mental disturbances (some-
times severe) affecting them in many different ways. The
level of seriousness has also been indicated in the official
spontaneous reports made to the Swedish MPA in 2011
where almost half (49.7%) of a total of 597 reports from
the general public were deemed serious [11]. Numerous
KILEN narratives reported experiencing a kind of blunt-
ing affect of the drug, making patients perceiving feeling
like ‘zombies’ incapable of having or sharing feelings to-
wards others, even their own family members:
“I felt completely blunted, that something controlled
me so I no longer had contact with my feelings
anymore. I became like a zombie who was completely
indifferent to everything.” Female, aged 22 years
(Sertraline).
This blunting affect has been described in other re-
search as well, where ‘being-on-SSRIs’ meant an increased
distance between takers and their worlds and where previ-
ously emotionally close became no more important than
‘anyone else’ [15]. This feeling of distance was sometimes
described in the KILEN narratives as a kind of deper-
sonalization or of feeling a sensation of unreality. In a pre-
vious study on the KILEN consumer reports, feeling a
sensation of unreality was a commonly reported mental
disturbance, but was not listed at all as an adverse drugles of patients’ statements in the KILEN consumer
ning unit Main-category Sub-category








o warnings of side effects Lack of
communication
to end drug treatment
e doctor.
Trust and distrust
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Reference FASS (building on the Summary of Product
Characteristics SPC) [9].
Some of the KILEN reports contained narratives de-
scribing an increase in having suicidal thoughts or of such
thoughts newly occurring. Despite its seriousness this is
not something new. Already in the early 1990s Teicher
and colleagues showed that some depressed patients (free
of recent serious suicidal ideation) developed intense and
violent suicidal preoccupation after 2–7 weeks of SSRI
treatment [16], and that antidepressant medication might
interfere with normal neuropsychological processes that
keep suicidal thoughts from intruding into consciousness
[17]. Experiencing suicidal thoughts in everyday life
affected patients to a high degree, according to their nar-
ratives in the KILEN material:
“Difficulties concentrating at work, having suicidal
thoughts.” Male, aged 45 years (Venlafaxine).
Obviously it is in self-reported material often uncer-
tain whether suicidal thoughts were evident before medi-
cation started or if they were a direct result of the use of
antidepressants, but it is nevertheless important to high-
light this severe psychiatric derangement, since it may
have fatal consequences if ignored. One must not forget
that the role of antidepressants in suicide prevention is
considered a major public health question given the high
prevalence of both depression and depression-related
suicidality [18].
Only 16 (8.8%) consumer narratives out of the total 181
included in the study contained positive experiences of
antidepressant drug treatment. This may be compared to
a Swedish study of antidepressant medication in primary
care where almost 67% of responding patients thought
that the drug made them feel better (women 70.2% and
men 58.5%) [19]. It is also important not forget that the
blunting affect of the drug can sometimes be perceived as
positive. Previous research has shown that the experience
of younger women is that the antidepressant drug enables
them to function in daily life activities [20]. The drug is
perceived as working by alleviating pain and suffering
[15], by suppressing sensations and stopping the person
from dwelling on symptoms [21]. Patients whose narra-
tives were positive about drug treatment in the KILEN
data often emphasized that the experienced side effect of
the antidepressant was a price worth paying, since the
prior untreated condition had been much worse:
“Saved me from total collapse; sure, there have been
shorter episodes of depression, but without Paroxetine
[Swedish antidepressant brand name – authors’ note]
or something like it, I would have been dead or have
killed someone.” Male, aged 42 years (Paroxetine).Discontinuation symptoms
According to KILEN narratives, it was especially during
discontinuation of antidepressant drugs that suspected
psychiatric adverse reactions were experienced:
“Discontinuation of antidepressant medication in four
days on doctor’s orders, from normal dosage of 50 mg
to 25 mg in four days and then nothing. After three
days, I experienced a fear of dying and extreme
anxiety and had several panic attacks . . . woke up
and found myself standing with a knife towards my
stomach on one occasion and on another with the
bathrobe belt in my hand. I no longer tolerate any
stress at all, which makes me panic and experience
dizziness. Have been without antidepressant
medication for nine days and experiences hell on
earth.” Female, aged 35 years (Sertraline).
A previous study on the KILEN material indicated that
adverse reactions in connection with discontinuation of
antidepressant medication was often reported to KILEN
but not always mentioned in the Swedish Physicians’ Desk
Reference FASS, and when it was mentioned, it was gener-
ally regarded as rare [9]. This has also been shown in an
evaluation of the UK patient reporting system ‘Yellow
Card Scheme’ which identified new ‘serious’ reactions not
previously included in the SPC [5]. Research has shown
that antidepressant discontinuation in depressed patients
can be associated with worsened depression and increased
suicidality [22], and that the recurrence risk for depression
was much shorter after rapid than after gradual discon-
tinuation of antidepressants [23]. Abrupt discontinuation
can also cause a larger increase in the number of adverse
discontinuation symptoms [24,25], and a report from the
Swedish Council on Technology Assessment in Health
Care (SBU) indicated that long-term use of antidepres-
sants (particularly in high dosages) could cause these
symptoms if treatment is terminated suddenly or the dos-
age is substantially reduced [26].
Fear of discontinuation symptoms made some patients
afraid of ending their treatment; these patients often con-
tinued to take antidepressants, despite the fact that they
did not want to be dependent on them. The suspected ad-
verse reactions were not just perceived as unpleasant but
also created a fear of stopping taking the antidepressant
drug. A concern that the depression might return was one
common feeling that was expressed:
“And when the death wish comes, I become so afraid
that I start again.” Female, aged 42 years
(Citalopram).
Since the psychiatric events reported to KILEN often
may also occur as a symptom of the illness for which the
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may easily suggest that the patient is having a relapse and
needs continued treatment. Distinguishing withdrawal
from relapse is important but often also very difficult.
Lack of communication
A second main category concerned the communication be-
tween patient and doctor, or rather its absence. Several
KILEN narratives concerned patients experiencing a lack of
information regarding adverse reactions from their doctor:
“When I first started taking it, I received NO [sic]
warning of adverse drug reactions.” Female, aged 37
years (Venlafaxine).
If patients are not receiving information about potential
adverse reactions, it is indeed worrying. According to
treatment recommendations from the Swedish MPA, all
patients with depressive symptoms should be met with
understanding and empathy and have (their) opportunity
to talk about their life situation, feelings and experience, as
well as receive information about the disorder and its
treatment options; this includes information about the
effects of a drug and its potential adverse reactions [27].
However, previous studies have also provided indications
that physicians rarely make reference to side effect (in only
16 of 34 consultations) [28], that patients are unaware that
suspected adverse reactions may occur [29], and patients
may believe that physicians are withholding information
about these reactions [30]. There is also the possibility that
physicians themselves are not fully aware of the side effects
or adverse reactions related to the drugs they prescribe.
Such situations may lead to poor communication be-
tween physicians and patients, which may in turn increase
risks [31]. Patients need, for example to be warned about,
and monitored for, the possibility of increased depressive
and suicidal symptoms as part of a discontinuation reac-
tion. This is also of great importance because feelings of
uncertainty regarding the safety of a drug are an import-
ant reason for nonadherence to treatment [32]. Fear of ad-
verse effects can be a main reason for not accepting SSRI
treatment [33]. Some KILEN reports included, for in-
stance, narratives of giving up on antidepressant treatment
because of difficult suspected adverse reactions:
“Moreover, I had nightmares every night, from the
moment I fell asleep, and I woke up several times every
night soaked in sweat. Unable to get enough sleep, I
became more strained. These adverse drug reactions were
the major cause for me to give up my antidepressant
treatment.” Female, aged 27 years (Sertraline).
Robust and clear communications between doctor and
patient if and when the patients experiences seriousadverse effects is therefore of great importance, since
serious events like suicidal thoughts or attempts may
continue to affect patients’ lives long after the event
[34]. However, it is important to acknowledge that com-
munications about the safety of medicines are complex
and generally poorly performed, and that differences in
risk perception between the public and healthcare pro-
fessionals exist, which may be a barrier to clear commu-
nication [35]. It is therefore vital that we challenge
potential communication obstacles in order to provide a
safer prescription culture. Patients need a balance of in-
formation about antidepressants so that they can decide
whether or not to take (or continue to take) drugs pre-
scribed [36]. It is however important to acknowledge
that doctors alone are not to be held responsible for this
lack of information. For instance, a British study indi-
cated that the patient information leaflet (PIL), that ac-
companies antidepressant medication, did not always
warn of discontinuation symptoms and also presented
side effects in a strikingly heterogeneous way, making it
difficult for patients to find the required information
needed to make an informed choice [36].
In some cases in the KILEN reports patients described
not just a lack of communication between doctor and
patient, but also that there were no follow-ups of the
treatment, and that prescriptions were renewed without
a personal contact, for instance, by telephone:
“The most appalling thing during all these years of
medication was that I did not have any contact with
somebody who monitored . . .either when I started, or
during, or after I stopped taking my medication.”
Female, aged 23 years (Paroxetine).
The Swedish National Board of Health and Welfare
argues that the most important measure to minimize risks
is to evaluate the effect of the prescribed antidepressant
drug, and on a regular basis review the treatment, so that
the patient does not continue to take a drug without clear
indication [19]. However, according to a study of anti-
depressant medication in primary care, the agency found
that only 40% of Swedish patients had an appointment for
follow-up, and over 60% of these had used antidepressant
drugs for over a year [19]. Since antidepressants drugs are
relatively often involved in the fatal adverse drug reactions
(FADRs) occurring [37] (even if it is a small number of
FADRs that occur in total) the extra need for surveillance
is worth highlighting. Talking with patients about what
influences their decisions about use of medications could
affect whether these medications are used optimally [30].
Otherwise, there is risk of poor or inappropriate prescrib-
ing, wastage of drugs and unsatisfactory doctor–patient
relationships if doctors’ perceptions do not correspond
with patients’ preferences [38].
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In a third main category, some patients referred to los-
ing trust in their doctor when they perceived that he or
she did not take the patient’s story and description of
ADRs seriously and/or scaled down their consequences.
According to several patient reports, there were some-
times problems of separating the symptoms related to
the diagnosed depression from the suspected adverse
reactions, where patients almost always interpreted
negative experiences as belonging to the drug while the
doctor construed them as evidence of the initial depres-
sion recurring.
“She [the doctor – author’s note] ignores
discontinuation symptoms from the drug and wants
me to start medicating again after I have been through
ten days of hell. She believes that my depression has
returned. . . It is totally wrong.” Female, aged 35 years
(Sertraline).
The conflicting accounts between patients and doctors
of either drug-induced reactions or initial illness symp-
toms were especially present during discontinuation.
Some patients reported to KILEN that they perceived
discontinuation symptoms over a longer period of time,
which they perceived as being dismissed by their doctor.
Previous research, however, has indicated that discon-
tinuation symptoms sometimes can be severe and pro-
longed, and may also be mistaken for signs of physical
illness or even early signs of relapse, leading to an over-
estimate of the true effect of the medication [39]. This is
unfortunate, since studies have shown that patients can
distinguish between suspected adverse reactions and
other symptoms [40] and are capable of providing clear
descriptions of their experiences and of balancing the
benefits and burden of treatment [6]. Some patients
reported losing confidence in their doctor when they
were not believed about the suspected adverse reactions
they experienced:
“Decided to discontinue after three years of ‘chemical
terror’, WITHOUT [sic] doctor’s approval.” Female,
aged 41 years (Paroxetine).
Patients have witnessed dismissive attitudes among
health care professionals in other patient reporting systems
as well (in this case, the UK ‘Yellow Card Scheme’) [41]. In
the KILEN study, the lack of trust towards the treating
doctor made some patients attempt to discontinue their
antidepressant treatment on their own, sometimes
abruptly leading to severe adverse symptoms as a conse-
quence. It is important that mutual trust exists between
patients and doctors in order to prevent non-adherence.
Doctors with better communication and interpersonalskills are able to detect problems earlier, can prevent med-
ical crisis and expensive intervention, and provide better
support to their patients [42].
As indicated in this study, consumer reporting may be
an additional way of detecting harmful effects that may
have been missed in clinical trials. Patient/consumer
reports (as contrasted to those reported by health pro-
fessionals) come straight from the person who has
experienced the drug effect(s); they describe the effect
on the person’s life [5,43,44]. It is hoped that the new
EU-legislation on pharmacovigilance [1] will help to
stimulate the systematic reporting by patients; in this
way more attention can also be paid to how drug-related
problems are experienced by patients themselves.
Limitations
The study has several limitations. The KILEN data ma-
terial was based on spontaneous consumer reports and
thereby was selected material, which might have exag-
gerated a negative view and experience of antidepressant
drug treatment. It is therefore unlikely that all views and
experiences of antidepressants have been captured. Since
it is an Internet-based reporting system, it will most
likely benefit younger individuals who are used to hand-
ling a computer, but by missing out on the older age
groups one risks getting a biased view of patients’
experiences of treatment. A Danish study showed for in-
stance that older female patients with depressive dis-
order had more negative views of the doctor–patient
interaction and of antidepressants [45].
There is also the issue of gender. In a previous study, it
was indicated that women reported ADRs to KILEN in a
much higher degree: between three and four times more
often than men, and sometimes more within certain age
groups [9]. This may also be true for the use of these
drugs. In this study, women accounted for 75% of the
reported narratives. This may be an effect of women, pos-
sibly to a higher degree, turning to non-profit organiza-
tions for help. It may also be an effect of women tending
to have a higher risk of ADRs than men, which increases
with age and increased numbers of drugs prescribed [46].
This could also explain women’s over-representation in
ADR reporting to KILEN. Furthermore, we do not know
how reporting consumers/patients were ‘officially’ diag-
nosed with depression (ICD-10, DSM IV or other), and
we do not know if the reported diagnosis was a ‘valid’ one,
since we only have the patients’ own reported experiences
to the KILEN website. It is also important to acknowledge
that this was only the patients’ perception of ADRs and
doctor–patient communication, and we do not have doc-
tors’ perceptions to compare with.
Lastly, there is the question of potential problems with
polypharmacy, with an unknown interaction between psy-
chotropic drugs, for instance, different antidepressants
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reported suspected adverse reaction is a result of a specific
medication or the combination of a number of medica-
tions. As indicated by a Swedish study, the prevalence of
polypharmacy, as well as the mean number of dispensed
drugs per individual increased, for instance, year-by-year
in Sweden from 2005 to 2008 [47].
Despite the limitations of this study, the data are still
of value since the material provides unique information
of consumer reporting (in Sweden) and patients’ qualita-
tive experiences of antidepressant treatment and sus-
pected adverse reactions.
Conclusions
The present study indicates that free text comments as
often contained in case reports directly submitted by
patients can be of value in pharmacovigilance and pro-
vide important information on how a drug may affect
the person using it and influence his or her personal life.
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